What is Nyxoah?
Headquartered in Mont-Saint-Guibert, Belgium, Nyxoah is a specialized medical technology enterprise dedicated to the development and commercialization of advanced solutions for Obstructive Sleep Apnea. By focusing on neurostimulation and other innovative therapeutic modalities, the company addresses the critical unmet needs of patients suffering from sleep-disordered breathing. Nyxoah occupies a strategic position within the MedTech landscape, bridging the gap between traditional CPAP therapy and surgical intervention through its patient-centric, technology-driven approach to chronic condition management.
How much funding has Nyxoah raised?
Nyxoah has raised a total of $371.7M across 8 funding rounds:
Series A
$11M
Private Equity
$20M
Private Equity
$27.2M
Stock Offering
$99.6M
Share Placement
$15M
Share Placement
$27M
Stock/Share Issuance
$77M
Private Equity
$95M
Series A (2014): $11M, investors not publicly disclosed
Private Equity (2016): $20M led by Novallia and Glide Healthcare
Private Equity (2020): $27.2M supported by Resmed Inc
Stock Issuance/Offering (2020): $99.6M, investors not publicly disclosed
Share Placement (2023): $15M, investors not publicly disclosed
Share Placement (2024): $27M, investors not publicly disclosed
Stock/Share Issuance (2025): $77M led by ResMed and Cochlear
Private Equity (2026): $95M, investors not publicly disclosed
Key Investors in Nyxoah
Gilde Healthcare
A specialized healthcare investment firm managing over 1.4 billion euros across venture, growth, and private equity strategies, focusing on businesses that enable better care at lower costs.
ResMed
A global healthcare technology leader that develops cloud-connected medical devices and software to improve the management of sleep disorders and respiratory conditions.
Cochlear
An Australian-based medical device company specializing in the design and manufacture of advanced hearing implant systems, including cochlear and bone conduction implants.
What's next for Nyxoah?
With the recent influx of $95M, Nyxoah is poised to enter a new phase of enterprise-level scaling. The company's strategic roadmap likely involves the expansion of its clinical trial programs and the strengthening of its commercial infrastructure to support broader market penetration. By leveraging its deep-rooted partnerships with industry giants like ResMed and Cochlear, Nyxoah is well-positioned to navigate the complex regulatory and competitive environments of the global healthcare market. Future growth will likely be driven by the continued adoption of its OSA treatment platforms, as the firm seeks to solidify its status as a leader in the digital health and sleep medicine sectors.
See full Nyxoah company page
